Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
复制标题
DOI：
10.1016/j.virol.2007.10.006
复制
发表时间：
2008-01-20
期刊：
影响因子：
3.7
通讯作者：
Quer, Josep
中科院分区：
文献类型：
--
作者：
Cubero, Maria;Esteban, Juan Ignacio;Quer, Josep
越来越多的新型丙型肝炎病毒NS 3蛋白酶抑制剂正在评估用于治疗慢性丙型肝炎。在体内和体外均显示了对蛋白酶抑制剂具有抗性的突变体的处理诱导的选择。一种特异性突变A156 T已被证明可赋予对几种此类药物的高水平耐药性（BILN 2061、VX-950、SCH 446211（SCH 6）和SCH 503034）。在这里，我们报告的A156 T突变的存在下，在接近1%的NS 3序列内的肝准种的慢性丙型肝炎患者从未与抗NS 3蛋白酶抑制剂治疗。(c)2007爱思唯尔公司All rights reserved.
An increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis C. Treatment-induced selection of mutants conferring resistance to protease inhibitors has been shown both in vivo and in vitro. A specific mutation, A156T has been shown to confer high-level resistance to several such agents (BILN2061, VX-950, SCH446211 (SCH6) and SCH503034). Here we report the presence of the A156T mutation in close to 1% of NS3 sequences within the liver quasispecies of a chronic hepatitis C patient never treated with anti-NS3-protease inhibitors. (c) 2007 Elsevier Inc. All rights reserved.